NCOG-29. THE NEURO-ONCOLOGY MAGNITUDE OF CLINICAL BENEFIT SCALE (NEURO-MCBS) AS A COMPREHENSIVE AND CLINICALLY RELEVANT ASSESSMENT TOOL TO DETERMINE CLINICAL BENEFIT FROM TARGETED THERAPIES IN CNS TUMORS
Kurz S, Renovanz M, Rieger J, Bombach P, Grosse L, Rieger D, Hucker S, Hille H, Hippler M, Oener O, Ruhm K, Beha J, Malek H, Moeller Y, Bitzer M, Malek N, Tabatabai G. NCOG-29. THE NEURO-ONCOLOGY MAGNITUDE OF CLINICAL BENEFIT SCALE (NEURO-MCBS) AS A COMPREHENSIVE AND CLINICALLY RELEVANT ASSESSMENT TOOL TO DETERMINE CLINICAL BENEFIT FROM TARGETED THERAPIES IN CNS TUMORS. Neuro-Oncology 2023, 25: v220-v220. PMCID: PMC10639832, DOI: 10.1093/neuonc/noad179.0842.Peer-Reviewed Original ResearchProgression-free survivalCNS tumorsBrain metastasesTargeted therapyClinical benefitTherapy optionsFirst-line therapy optionTreatment efficacyDegree of clinical benefitClinical utilityMagnitude of Clinical Benefit ScaleNeuro-oncological conditionsSecondary CNS tumorsOutcome dataPhase I studyComprehensive molecular profilingOff-label therapyOutcome measuresAssessment of treatment efficacyClinical outcome dataAssess treatment efficacySurvival outcome dataPFS2/PFS1 ratioLongitudinal observational studyPerformance statusClinical utility of whole-genome DNA methylation profiling as a primary molecular diagnostic assay for central nervous system tumors—A prospective study and guidelines for clinical testing
Galbraith K, Vasudevaraja V, Serrano J, Shen G, Tran I, Abdallat N, Wen M, Patel S, Movahed-Ezazi M, Faustin A, Spino-Keeton M, Roberts L, Maloku E, Drexler S, Liechty B, Pisapia D, Krasnozhen-Ratush O, Rosenblum M, Shroff S, Boué D, Davidson C, Mao Q, Suchi M, North P, Hopp A, Segura A, Jarzembowski J, Parsons L, Johnson M, Mobley B, Samore W, McGuone D, Gopal P, Canoll P, Horbinski C, Fullmer J, Farooqi M, Gokden M, Wadhwani N, Richardson T, Umphlett M, Tsankova N, DeWitt J, Sen C, Placantonakis D, Pacione D, Wisoff J, Hidalgo E, Harter D, William C, Cordova C, Kurz S, Barbaro M, Orringer D, Karajannis M, Sulman E, Gardner S, Zagzag D, Tsirigos A, Allen J, Golfinos J, Snuderl M. Clinical utility of whole-genome DNA methylation profiling as a primary molecular diagnostic assay for central nervous system tumors—A prospective study and guidelines for clinical testing. Neuro-Oncology Advances 2023, 5: vdad076. PMID: 37476329, PMCID: PMC10355794, DOI: 10.1093/noajnl/vdad076.Peer-Reviewed Original ResearchCNS tumorsProspective studyHistologic diagnosisCentral nervous system tumorsDiagnostic accuracyCentral nervous system cancerPrimary CNS tumorsNervous system tumorsNervous system cancersCancer-associated deathsClinical trial designDiagnostic errorsPrimary diagnostic methodDNA methylation profilingMolecular diagnostic testsPrognostic subclassificationPediatric patientsHistologic subtypeWhole genome DNA methylation profilingDefinitive diagnosisPrognostic informationSystem tumorsSystem cancersPatient managementClinical utilityClinical outcome of biomarker-guided therapies in adult patients with tumors of the nervous system
Renovanz M, Kurz S, Rieger J, Walter B, Becker H, Hille H, Bombach P, Rieger D, Grosse L, Häusser L, Skardelly M, Merk D, Paulsen F, Hoffmann E, Gani C, Neumann M, Beschorner R, Rieß O, Roggia C, Schroeder C, Ossowski S, Armeanu-Ebinger S, Gschwind A, Biskup S, Schulze M, Fend F, Singer S, Zender L, Lengerke C, Brucker S, Engler T, Forschner A, Stenzl A, Kohlbacher O, Nahnsen S, Gabernet G, Fillinger S, Bender B, Ernemann U, Öner Ö, Beha J, Malek H, Möller Y, Ruhm K, Tatagiba M, Schittenhelm J, Bitzer M, Malek N, Zips D, Tabatabai G. Clinical outcome of biomarker-guided therapies in adult patients with tumors of the nervous system. Neuro-Oncology Advances 2023, 5: vdad012. PMID: 36915613, PMCID: PMC10007909, DOI: 10.1093/noajnl/vdad012.Peer-Reviewed Original ResearchBiomarker-guided therapyAdult patientsMolecular profilingNeuro-oncology patientsAdvanced tumorsClinical utilityTargeted therapyNervous systemClinical trialsTherapy recommendationsComprehensive molecular profilingInclusion of patientsData cutoffClinical benefitClinical outcomesTumorTherapyPatientsEvidence levelClinical careTrialsMtbTranslation studiesInvestigate feasibility